Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

And yet another Evomela study (NCT02909036) started in Sept by Memorial Sloan Kettering Cancer Center. This is just a P1 PK study but I found part of the write-up informative on the value of Evomela

"Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its effect or need to be administered quickly after being mixed). It may also have fewer side effects such as problems with important levels of body electrolytes such as potassium, phosphorous and magnesium; and cause less kidney and heart damage] than standard formulation melphalan."